-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anti-CD19 UCAR-NK Cells in Hematological Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anti-CD19 UCAR-NK Cells in Hematological Tumor Drug Details: Gene therapy is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Plasma Cell Neoplasm Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Refractory Multiple Myeloma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Taa06-Ucar-Gammadeltat in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Taa06-Ucar-Gammadeltat in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Taa06-Ucar-Gammadeltat in Relapsed Acute Myeloid LeukemiaDrug Details:TAA06-UCAR-gammadeltaT is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Taa06-Ucar-Gammadeltat in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Taa06-Ucar-Gammadeltat in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Taa06-Ucar-Gammadeltat in Refractory Acute Myeloid LeukemiaDrug Details:TAA06-UCAR-gammadeltaT is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTD-401 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTD-401 in Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CTD-401 in Non-Hodgkin Lymphoma Drug Details:CTD-401 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pritelivir in Simplexvirus (HSV) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pritelivir in Simplexvirus (HSV) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Pritelivir in Simplexvirus (HSV) Infections Drug Details:Pritelivir (AIC-316, BAY-571293) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pertuzumab Biosimilar in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pertuzumab Biosimilar in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Pertuzumab Biosimilar in Metastatic Breast Cancer Drug Details:Pertuzumab biosimilar is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SHR-1702 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SHR-1702 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SHR-1702 in Relapsed Acute Myeloid Leukemia Drug Details: SHR-1702 is...